Literature DB >> 20600676

Cortical kynurenic acid bi-directionally modulates prefrontal glutamate levels as assessed by microdialysis and rapid electrochemistry.

A Konradsson-Geuken1, H Q Wu, C R Gash, K S Alexander, A Campbell, Y Sozeri, R Pellicciari, R Schwarcz, J P Bruno.   

Abstract

Using two in vivo methods, microdialysis and rapid in situ electrochemistry, this study examined the modulation of extracellular glutamate levels by endogenously produced kynurenic acid (KYNA) in the prefrontal cortex (PFC) of awake rats. Measured by microdialysis, i.p. administration of KYNA's bioprecursor L-kynurenine dose-dependently elevated extracellular KYNA and reduced extracellular glutamate (nadir after 50 mg/kg kynurenine: 60% decrease from baseline values). This dose-dependent decrease in glutamate levels was also seen using a glutamate-sensitive microelectrode array (MEA) (31% decrease following 50 mg/kg kynurenine). The kynurenine-induced reduction in glutamate was blocked (microdialysis) or attenuated (MEA) by co-administration of galantamine (3 mg/kg i.p.), a drug that competes with KYNA at an allosteric potentiating site of the alpha 7 nicotinic acetylcholine receptor. In separate experiments, extracellular glutamate levels were measured by MEA following the local perfusion (45 min) of the PFC with kynurenine (2.5 microM) or the selective KYNA biosynthesis inhibitor S-ethylsulfonylbenzoylalanine (S-ESBA; 5 mM). In agreement with previous microdialysis studies, local kynurenine application produced a reversible reduction in glutamate (nadir: -29%), whereas perfusion with S-ESBA increased glutamate levels reversibly (maximum: +38%). Collectively, these results demonstrate that fluctuations in the biosynthesis of KYNA in the PFC bi-directionally modulate extracellular glutamate levels, and that qualitatively very similar data are obtained by microdialysis and MEA. Since KYNA levels are elevated in the PFC of individuals with schizophrenia, and since prefrontal glutamatergic and nicotinic transmission mediate cognitive flexibility, normalization of KYNA levels in the PFC may constitute an effective treatment strategy for alleviating cognitive deficits in schizophrenia. (c) 2010 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20600676      PMCID: PMC2918728          DOI: 10.1016/j.neuroscience.2010.05.052

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  75 in total

1.  The continuing problem of false positives in repeated measures ANOVA in psychophysiology: a multivariate solution.

Authors:  M W Vasey; J F Thayer
Journal:  Psychophysiology       Date:  1987-07       Impact factor: 4.016

2.  An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid.

Authors:  M N Perkins; T W Stone
Journal:  Brain Res       Date:  1982-09-09       Impact factor: 3.252

3.  Synthesis and metabolism of L-kynurenine in rat brain.

Authors:  E M Gál; A D Sherman
Journal:  J Neurochem       Date:  1978-03       Impact factor: 5.372

4.  Determination of extracellular kynurenic acid in the striatum of unanesthetized rats: effect of aminooxyacetic acid.

Authors:  C Speciale; H Q Wu; J B Gramsbergen; W A Turski; U Ungerstedt; R Schwarcz
Journal:  Neurosci Lett       Date:  1990-08-14       Impact factor: 3.046

5.  A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists.

Authors:  M Kessler; T Terramani; G Lynch; M Baudry
Journal:  J Neurochem       Date:  1989-04       Impact factor: 5.372

6.  Cerebral synthesis and release of kynurenic acid: an endogenous antagonist of excitatory amino acid receptors.

Authors:  K J Swartz; M J During; A Freese; M F Beal
Journal:  J Neurosci       Date:  1990-09       Impact factor: 6.167

7.  Rat brain slices produce and liberate kynurenic acid upon exposure to L-kynurenine.

Authors:  W A Turski; J B Gramsbergen; H Traitler; R Schwarcz
Journal:  J Neurochem       Date:  1989-05       Impact factor: 5.372

8.  Endogenous kynurenic acid disrupts prepulse inhibition.

Authors:  Sophie Erhardt; Lilly Schwieler; Carolina Emanuelsson; Mark Geyer
Journal:  Biol Psychiatry       Date:  2004-08-15       Impact factor: 13.382

9.  Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism.

Authors:  S Fukui; R Schwarcz; S I Rapoport; Y Takada; Q R Smith
Journal:  J Neurochem       Date:  1991-06       Impact factor: 5.372

10.  Effect of nicotine on levels of extracellular amino acids in regions of the rat brain in vivo.

Authors:  E Toth; E S Vizi; A Lajtha
Journal:  Neuropharmacology       Date:  1993-08       Impact factor: 5.250

View more
  36 in total

1.  Age dependency of inhibition of alpha7 nicotinic receptors and tonically active N-methyl-D-aspartate receptors by endogenously produced kynurenic acid in the brain.

Authors:  Manickavasagom Alkondon; Edna F R Pereira; Howard M Eisenberg; Yasushi Kajii; Robert Schwarcz; Edson X Albuquerque
Journal:  J Pharmacol Exp Ther       Date:  2011-01-26       Impact factor: 4.030

2.  Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the alpha7 positive modulator galantamine.

Authors:  Kathleen S Alexander; Hui-Qiu Wu; Robert Schwarcz; John P Bruno
Journal:  Psychopharmacology (Berl)       Date:  2011-10-26       Impact factor: 4.530

3.  Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia.

Authors:  Korrapati V Sathyasaikumar; Erin K Stachowski; Ikwunga Wonodi; Rosalinda C Roberts; Arash Rassoulpour; Robert P McMahon; Robert Schwarcz
Journal:  Schizophr Bull       Date:  2010-10-29       Impact factor: 9.306

4.  Inhibition of Large Neutral Amino Acid Transporters Suppresses Kynurenic Acid Production Via Inhibition of Kynurenine Uptake in Rodent Brain.

Authors:  Airi Sekine; Yusuke Kuroki; Tomomi Urata; Noriyuki Mori; Tsutomu Fukuwatari
Journal:  Neurochem Res       Date:  2016-05-09       Impact factor: 3.996

5.  Endogenous activation of nAChRs and NMDA receptors contributes to the excitability of CA1 stratum radiatum interneurons in rat hippocampal slices: effects of kynurenic acid.

Authors:  Manickavasagom Alkondon; Edna F R Pereira; Edson X Albuquerque
Journal:  Biochem Pharmacol       Date:  2011-06-13       Impact factor: 5.858

6.  Inhibition of kynurenine aminotransferase II attenuates hippocampus-dependent memory deficit in adult rats treated prenatally with kynurenine.

Authors:  Ana Pocivavsek; Greg I Elmer; Robert Schwarcz
Journal:  Hippocampus       Date:  2018-12-04       Impact factor: 3.899

Review 7.  Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis.

Authors:  Eric Plitman; Yusuke Iwata; Fernando Caravaggio; Shinichiro Nakajima; Jun Ku Chung; Philip Gerretsen; Julia Kim; Hiroyoshi Takeuchi; M Mallar Chakravarty; Gary Remington; Ariel Graff-Guerrero
Journal:  Schizophr Bull       Date:  2017-07-01       Impact factor: 9.306

8.  Preferential Disruption of Prefrontal GABAergic Function by Nanomolar Concentrations of the α7nACh Negative Modulator Kynurenic Acid.

Authors:  Eden Flores-Barrera; Daniel R Thomases; Daryn K Cass; Ajay Bhandari; Robert Schwarcz; John P Bruno; Kuei Y Tseng
Journal:  J Neurosci       Date:  2017-07-20       Impact factor: 6.167

9.  Salivary kynurenic acid response to psychological stress: inverse relationship to cortical glutamate in schizophrenia.

Authors:  Joshua Chiappelli; Laura M Rowland; Francesca M Notarangelo; S Andrea Wijtenburg; Marian A R Thomas; Ana Pocivavsek; Aaron Jones; Krista Wisner; Peter Kochunov; Robert Schwarcz; L Elliot Hong
Journal:  Neuropsychopharmacology       Date:  2018-04-18       Impact factor: 7.853

10.  Prenatal kynurenine exposure in rats: age-dependent changes in NMDA receptor expression and conditioned fear responding.

Authors:  Michelle L Pershing; David Phenis; Valentina Valentini; Ana Pocivavsek; Derick H Lindquist; Robert Schwarcz; John P Bruno
Journal:  Psychopharmacology (Berl)       Date:  2016-08-16       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.